Open AccessLuspatercept (Reblozyl)
Author(s) -
Reimbursement Team
Publication year - 2022
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2022.261
Subject(s) - reimbursement , medicine , vial , erythropoietin , anemia , family medicine , intensive care medicine , surgery , political science , health care , chemistry , law
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses luspatercept (Reblozyl), 25 mg per vial, 75 mg per vial, powder for solution for SC injection.Indication: For the treatment of adult patients with transfusion-dependent anemia requiring at least 2 RBC units over 8 weeks resulting from very low- to intermediate-risk MDS who have ring sideroblasts and who have failed or are not suitable for erythropoietin-based therapy.